JAIDS Journal of Acquired Immune Deficiency Syndromes | 2021
HIV pre-exposure prophylaxis in the time of COVID-19: How a robust and responsive HIV PrEP intervention can avert loss of HIV prevention coverage during a global pandemic.
Abstract
REFERENCES 1. Hulgan T. Factors associated with insulin resistance in adults with HIV receiving contemporary antiretroviral therapy: a brief update. Curr HIV AIDS Rep. 2018;15:223–232. 2. Blümer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227–236. 3. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitorassociated diabetes. J Acquir Immune Defic Syndr. 1999;21:209–216. 4. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIVinfected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–1229. 5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58. 6. Dirajlal-Fargo S, Moser C, Brown TT, et al. Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS clinical trials group A5260s. Open Forum Infect Dis. 2016;3:ofw174. 7. Gianotti N, Muccini C, Galli L, et al. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens. J Med Virol. 2019;91:1937–1943. 8. Younas M, Psomas C, Reynes J, et al. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med. 2016;17:89–105. 9. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV type 1infected elite controllers. J Infect Dis. 2014;209:931–939. 10. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. 11. Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–E26. 12. Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70:1267–1274. 13. Assoumou L, Racine C, Fellahi S, et al. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. AIDS. 2020;34: 1859–1862. 14. Burns JE, Stirrup OT, Dunn D, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS. 2020;34:109–114. 15. Dubé MP, Johnson DL, Currier JS, et al. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713–714. 16. Fong PS, Flynn DM, Evans CD, et al. Integrase strand transfer inhibitor‐associated diabetes mellitus: a case report. Int J STD AIDS. 2017;28:626–628. 17. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/ lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based threeor four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study. Clin Infect Dis. 2020;6:ciz1243. 18. Racette SB, Evans EM, Weiss EP, et al. Abdominal adiposity is a stronger predictor of insulin resistance than fitness among 50-95 years old. Diabetes Care. 2006;29:673–678. 19. Mutimura E, Hoover DR, Shi Q, et al. Insulin resistance change and antiretroviral therapy exposure in HIV-infected and uninfected Rwandan women: a longitudinal analysis. PLoS One. 2015;10:e0123936.